Get the Stockscreener App
17.70
1.66%
-0.355
Dyne Therapeutics Inc stock is traded at $17.70, with a volume of 1.65M.
It is down -1.66% in the last 24 hours and up +14.29% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$18.06
Open:
$18.39
24h Volume:
1.65M
Relative Volume:
0.67
Market Cap:
$2.93B
Revenue:
-
Net Income/Loss:
$-412.89M
P/E Ratio:
-4.5868
EPS:
-3.86
Net Cash Flow:
$-361.93M
1W Performance:
+19.52%
1M Performance:
+14.29%
6M Performance:
+35.06%
1Y Performance:
+49.49%
1-Day Range:
$17.41
$18.80
1-Week Range:
$14.96
$20.03
52-Week Range:
$6.36
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
17.75 | 2.98B | 0 | -412.89M | -361.93M | -3.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.19 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.74 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
701.43 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.45 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.12 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-25-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-24-25 | Initiated | Bernstein | Mkt Perform |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Assessing Dyne Therapeutics (DYN) Valuation After Phase 3 HARMONIA Launch And New DELIVER Data - simplywall.st
5 Best Day Trading Stocks to Buy Now - Insider Monkey
Dyne Therapeutics launches phase 3 trial for DM1 treatment By Investing.com - Investing.com Nigeria
Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate, Shares Surge 11.8% - AlphaStreet
Dyne Therapeutics (DYN) Climbs 11.8% on Triple-Digit Price Target Upgrade - Finviz
Brian Posner Purchases 3,000 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock - MarketBeat
Nio, Zevra Therapeutics, Vertex Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - Benzinga
Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate; Shares Surge 19% - AlphaStreet
Jefferies Maintains Buy on Dyne Therapeutics (DYN) March 2026 - Meyka
Dyne Therapeutics (DYN) Receives Analyst Rating Update from Char - GuruFocus
Dyne Therapeutics (NASDAQ:DYN) Trading 11.2% HigherTime to Buy? - MarketBeat
Baird reiterates Dyne Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada
Stifel reiterates Dyne Therapeutics stock rating on DMD data By Investing.com - Investing.com Australia
Dyne Therapeutics: Strong DELIVER Data Strengthens The Bull Case (NASDAQ:DYN) - Seeking Alpha
Stifel reiterates Dyne Therapeutics stock rating on trial design By Investing.com - Investing.com Canada
Jones Trading reiterates Buy on Dyne Therapeutics stock after DMD, DM1 updates - Investing.com
Stifel reiterates Dyne Therapeutics stock rating on DMD data - Investing.com South Africa
Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) - Sahm
Rate Hike: Will Dyne Therapeutics Inc benefit from government policy2026 EndofMonth & High Win Rate Trade Alerts - baoquankhu1.vn
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 - Investing News Network
Dyne Therapeutics (DYN) Begins Phase 3 Trial for Myotonic Dystro - GuruFocus
Dyne Therapeutics (DYN) Reveals Encouraging Results from Zelecim - GuruFocus
Dyne Therapeutics starts Phase 3 HARMONIA trial for z-basivarsen in DM1 - Traders Union
Dyne Therapeutics launches phase 3 trial for DM1 treatment - Investing.com
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) - Bitget
150-patient Dyne trial focuses on myotonic dystrophy daily function - Stock Titan
Dyne Therapeutics Announces New Positive Cardiopulmonary Results From Deliver Trial Of Z-Rostudirsen In Duchenne Muscular Dystrophy (Dmd) - TradingView
Dyne DMD trial shows better breathing, heart health after 24 months - Stock Titan
DYN SEC FilingsDyne Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
HC Wainwright Predicts Higher Earnings for Dyne Therapeutics - MarketBeat
A Look At Dyne Therapeutics (DYN) Valuation After Q4 2025 Earnings Beat And Ongoing Clinical Progress - Yahoo Finance
FDA curtails Pepgen’s Freedom2 operate in DM1 - bioworld.com
Lifesci Capital Brokers Raise Earnings Estimates for DYN - MarketBeat
Q1 Earnings Estimate for DYN Issued By HC Wainwright - MarketBeat
Rafferty Asset Management LLC Boosts Stake in Dyne Therapeutics, Inc. $DYN - MarketBeat
DYN: Validated platform and pipeline set stage for multiple rare disease launches and growth - TradingView
Dyne Therapeutics, Inc. $DYN Shares Acquired by Vanguard Group Inc. - MarketBeat
A Look At Dyne Therapeutics (DYN) Valuation As Late Stage Pipeline And BLA Plans Gain Momentum - simplywall.st
Morgan Stanley Maintains 'Overweight' on DYN but Lowers Price Ta - GuruFocus
Dyne Therapeutics, Inc. (DYN) Stock Analysis: A Potential 142% Upside in the Biotech Arena - DirectorsTalk Interviews
Chardan Capital Maintains Buy Rating on Dyne Therapeutics (DYN) - GuruFocus
HC Wainwright & Co. Lowers Price Target for Dyne Therapeutics (D - GuruFocus
Analysts Offer Insights on Healthcare Companies: American Well (AMWL) and Dyne Therapeutics (DYN) - The Globe and Mail
Decoding Dyne Therapeutics Inc (DYN): A Strategic SWOT Insight - GuruFocus
Chardan reiterates Dyne Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
DYN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Overweight Maintained for Dyne Therapeutics (DYN) by Morgan Stanley March 2026 - Meyka
Raymond James reiterates Dyne Therapeutics stock rating on FDA pathway By Investing.com - Investing.com Canada
Dyne Therapeutics (NASDAQ:DYN) Shares Down 6.6% After Earnings Miss - MarketBeat
Morgan Stanley cuts Dyne Therapeutics stock price target on model update - Investing.com Canada
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dyne Therapeutics Inc Stock (DYN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kersten Dirk | Director |
Mar 09 '26 |
Sale |
17.72 |
177,690 |
3,148,987 |
5,285,156 |
0.18%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):